A New Treatment for Urethral Strictures

Milroy, E. J. G.; Cooper, JE; Wallsten, H; Chapple, Christopher R.; El-Din, Ahmed B. Shehab; Seddon, Andrew M.; Rowles, P M

doi:10.1016/s0140-6736(88)92238-6

Cited by 213 publications

(48 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UroLume stents initially demonstrated promising results for the treatment of urethral stricture disease [31]. In 2001, Elliott and Boone [32] reported successful outcomes in eight patients with recurrent BNC and PPI treated with a staged procedure to insert an UroLume stent followed by an AUS.…”

Section: Urolume Stentsmentioning

confidence: 99%

Management of the incontinent patient with a sphincteric stricture following radical prostatectomy

Cox

Herschorn

2014

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

Section: Urolume Stentsmentioning

confidence: 99%

Management of the incontinent patient with a sphincteric stricture following radical prostatectomy

Cox

Herschorn

2014

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…Ureter · Striktur · Therapie · Stent Nachdem 1988 erstmals durch Milroy [13] ein permanenter metallischer Stent erfolgreich in die Urethra implantiert worden war, wollte man diese Technik auch im oberen Harntrakt anwenden. Neue Systeme mussten entwickelt werden, um den anatomischen und physiologischen Gegebenheiten des Harnleiters gerecht zu werden.…”

Section: Schlüsselwörterunclassified

Selbstexpandierende permanente endoluminale Stents (SPES) zur Therapie der benignen Harnleiterobstruktion 6 Jahre eigene Erfahrung und Literaturübersicht

Pauer¹

2002

Urologe [A]

View full text Add to dashboard Cite

At the urologic department of the Public General Hospital in Wels between 1994 and 2000, a self-expanding permanent endoluminal stent (SPES) was implanted in 13 women and 1 man (mean age: 52.2 years) with ureteral strictures. All patients had previously been treated unsuccessfully. An open operative approach was not possible because of various contraindications or because the patient had refused surgery. During a total follow-up period of 730 months (median: 59.9 months), primary patency lasted 669.3 months (median: 47.8 months). In nine patients no further intervention was necessary, and in four patients patency could be regained by additional interventions. In one patient the kidney had to be removed because of progressive renal insufficiency. Worldwide 98 cases of a SPES implant have been published so far. The patency rate was 68 of 98 stents (69.3%). The implantation of a SPES in the ureter for benign and complicated strictures represents a serviceable alternative to other urinary diversions. Additional clinical and experimental studies and long-term results are needed to make a definitive assessment of this method.

show abstract

“…[1][2][3] The previous successful use of metal stents in the vascular system and the biliary tree has led several investigators to propose their use for urologic applications such as the treatment of benign prostatic hyperplasia, urethral strictures, and detrusor-sphincter dyssynergia. [4][5][6][7] Metal stents have also been used in the treatment of malignant and benign ureteral obstructions by others and us, with encouraging results. [1][2][3]8,9 Metal stents covered with various biocompatible materials have recently been introduced in vascular intervention for the treatment of both aneurysmal and occlusive peripheral arterial diseases.…”

Section: Introductionmentioning

confidence: 97%